NaF PET-CT
Phase 1Small molecule
NaF PET-CT is one of 41 small molecule programs targeting Stroke. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
150 competitors in Stroke
#DrugCompanyPhaseTrials
1Zometa
PfizerPreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Coumadin
AAbbott
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Stroke1 trial
A Novel Method for Determination of Thromboembolic Stroke Origin
Not yet recruiting·—·Phase 1·NCT06961604·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NaF PET-CT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAtlantic Health System